For half a century, depression treatments have largely targeted a class of neurotransmitters called monoamines. Recent drugs such as Prozac and Paxil, for example, work by blocking serotonin uptake, making more of the neurotransmitter available to stimulate neurons typically understimulated in depressed people. The monoamines are limited to particular tasks within the brain, however. A more general communication system relies on an amino acid called glutamate. The glutamate system is associated with learning and memory, but it has been increasingly implicated in mood regulation (ScienceNOW, 24 April 1998).
A team led by Carlos Zarate, a psychopharmacologist at the National Institute of Mental Health in Bethesda, Maryland, and colleagues targeted a key player in the glutamate system, a receptor known as N-methyl d-aspartate (NMDA). Seventeen patients, who had major depression and had not responded to traditional antidepressants, were injected with either a placebo or ketamine, a known NMDA receptor blocker. Based on their reported moods and the observations of the team, 12 responded to the treatment, with 5 of them meeting the criteria for remission of depression, the team reports in this month’s issue of Archives of General Psychiatry. In addition, 6 patients experienced relief for at least a week from the single injection.” (ScienceNOW)
